Dashboard
Weak Long Term Fundamental Strength with a 8.19% CAGR growth in Operating Profits over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.47 times
Stock is technically in a Mildly Bearish range
With ROCE of 6.4, it has a Expensive valuation with a 2 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
INR 151 Cr (Micro Cap)
30.00
40
0.00%
1.33
11.29%
3.36
Total Returns (Price + Dividend) 
Auro Labs. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Auro Laboratories Ltd is Rated Strong Sell
Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 19 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Auro Laboratories Ltd is Rated Strong Sell
Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 October 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Auro Laboratories Ltd is Rated Strong Sell
Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 July 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 18 October 2026, providing investors with the latest perspective on the company’s position.
Read More Announcements 
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
19-Nov-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Siddhartha Deorah HUF
Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSEAuro Laboratories Limited has submitted clippings of newpaper publications of the unaudited financial Results for the quarter and half year ended September 30 2026.
Board Meeting Outcome for Dated November 13 2026.
13-Nov-2026 | Source : BSEAuro Laboratories Limited has submitted the outcome of the Board Meeting dated November 13 2026.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (0.01%)
Held by 0 FIIs
Auro Impex Private Ltd (18.98%)
Kirtilaben Jayantilal Mehta (3.13%)
36.74%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 58.95% vs -10.78% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 11.43% vs 8.25% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 31.63% vs -62.61% in Sep 2024
Growth in half year ended Sep 2025 is -45.05% vs -58.58% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 76.92% vs -71.45% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 120.69% vs -78.56% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 58.45% vs -63.83% in Mar 2025
YoY Growth in year ended Mar 2026 is 91.85% vs -76.38% in Mar 2025